TR¹G 2024

Together Towards Tomorrow



36th TROG Cancer Research Annual Scientific Meeting 12 - 15 March 2024 | Newcastle NSW

TROG CANCER RESEARCH

EVENT PARTNER & WORKSHOP SPONSOR



A Siemens Healthineers Company

PLATINUM SPONSORS





GOLD SPONSOR



SOCIAL FUNCTION SPONSORS





BRONZE SPONSORS





Cipla









SESSION SPONSOR



BRAINLAB

MARK HUGHES FOUNDATION CENTRE FOR BRAIN CANCER RESEARCH

WORKSHOP SESSION SPONSORS



TrialDocs

Mater Newcastle



TROG 2024 12 - 15 March 2024 Newcastle NSW



Table of Contents

5
5
5
6
6
6
8
8
13
13
17
21
25
28
29

Attend and win prizes!

Go in the draw to win some great prizes, simply by visiting the exhibitors in the Concert Hall.

When you collect your name badge you'll receive your passport card (below). Obtain a stamp from each exhibitor, enter your details on the back and hand it to the registration desk staff.

The prize draw will occur during the closing comments on Friday 15 March.



CONFERENCE SECRETARIAT

ASN Events Pty Ltd 9/37 Smith Street Fitzroy, VIC 3065, Australia Contact person on-site:



Chris Dayson | M: +61 (0)413 608 373 | email: chris.d@asnevents.net.au

ARIA CORE

Finally, a complete **continuum of care** for all of oncology.

One solution. Endless possibilities. The single, seamless, connected system to actively manage patient information and drive workflows—**a new dimension in oncology care.**



Refer enquiries to Varian Medical Systems Australasia on 1800.657.036 or customerservice-anz@varian.com





DELEGATE INFORMATION

VENUES

SCIENTIFIC MEETING Newcastle City Hall 290 King St, Newcastle

GALA DINNER NEX (Newcastle Entertainment & Conference Centre) 309 King St, Newcastle West CREW & TRW WORSHOPS Peibri Place 97 Hannell St, Wickham

CREW & SMART WORSHOPS Newcastle Cruising Yacht Club (NCYC) 95 Hannell St, Wickham

WORKSHOPS

Technical Research Workshop (TRW) 9:00am - 5:00pm - Peibri Place

Statistical Methods, Evidence Appraisal & Research for Trainees Workshop (SMART) 8:30am - 6:00pm - NCYC Clinical Research Education Workshop (CREW) 9:00am - 11:00am - Peibri Place 11:00am - 5:00pm – NCYC

REGISTRATION DESK

DIETARY REQUIREMENTS

The registration desk will be open as followings:

Wednesday 13 March Thursday 14 March Friday 15 March

7:15 AM - 7:00 PM 7:15 AM - 5:00 PM 8:30 AM - 1:00 PM **Workshops** Served on a separate table in the catering space of your respective venue. Ask staff for directions.

Scientific Meeting

Served on a separate table in the Concert Hall. Ask staff for directions.

Gala Dinner

Upon arrival collect your dietary requirement table card at the entrance and place it in front of you at your table.

SOCIAL PROGRAM

All delegates are invited to attend the social functions however pre-registration is required. If your name badge does not include a ticket for these events and you would like to purchase one for yourself and/or someone else, please see the ASN staff at the registration desk about availability.

Welcome Reception

Date: Wednesday 13 March Time: 5:30 pm – 7:30pm Location: Newcastle City Hall Gala Dinner Date: Thursday 14 March Time: 7:00 pm – 11:00pm Location: The NEX Theme: Black tie on the beach



TROG 2024 12 - 15 March 2024 Newcastle NSW



MOBILE PROGRAM & WIFI

For easy access to the Meeting program, event information, exhibitor details, and note taking, open the Mobile Program using the QR code.

Newcastle City Hall Server: TROG Meeting 2024 Password: TROG2024

SPEAKER PRESENTATION INSTRUCTIONS

All plenary sessions take place in the Banquet Room. Audio-visual equipment will be supplied and there will be a technician on site to assist with any enquires. **Please make sure your presentation is in 16:9 format** to get the best image. All presentations must be pre-loaded onto the AV laptop prior to the session commencing. Please bring your presentation on a USB drive to the Banquet room during the break prior to your session. A presenter's tool (clicker) will be provided at the lectern.

POSTER PRESENTATION INSTRUCTIONS

Posters should be size A0 portrait orientation and can be attached to the poster boards with Velcro. Additional Velcro supplies can be obtained from the registration desk. The poster boards are located in the Concert Hall and numbered according to the Poster Listing in this handbook.

1/2 3 6 7 Cart 15/16 9 10 14 13 12 11 DIANC Booths 1 & 2 – Elekta Booth 11 - Cipla Booth 12 - Mundipharma Booth 3 – TROG Booth 13 – Oxford Scientific Booth 6 – alphaXRT Booth 14 – Icon Centre Booth 7 – ACDS Booths 15 & 16 - Varian Booth 8 - AIQ Solutions Booth 10 – Brainlab


EXHIBITION FLOOR PLAN & EXHIBITOR LISTING





World-class cancer care, close to home

Radiation Oncology | Medical Oncology | Haematology | Clinical Trials



- 38 cancer centres (and growing)
- (H) 200+ internationally recognised specialists
- Australia's largest private cancer clinical trials program
 - No wait list for consultation or treatment

Icon Cancer Centre is part of Icon Group - Australia's largest dedicated cancer care provider. Our mission is strong but simple - to deliver the best cancer care possible, to as many people as possible, as close to home as possible.

S



TROG 2024 12 - 15 March 2024 Newcastle NSW



KEYNOTE SPEAKERS



Prof. Stephen Kry The University of Texas MD Anderson Cancer Centre, USA

Dr. Stephen Kry is a board-certified tenured professor at The University of Texas MD Anderson Cancer Center where he serves as director and principal investigator of the National Cancer Institute's Imaging and Radiation Oncology Core and ensures the highest quality data for clinical trials.

He also serves as director of the Radiation Quality Assurance Laboratory and an Accredited Dosimetry Calibration Laboratory. Dr. Stephen Kry has extensive independent funding, more than 150 peer reviewed publications, and has mentored more than 40 graduate students. He is also a native Canadian and avid skier and hiker.



Prof. Stephane Supiot Institut de Cancérologie de l'Ouest, University of Nantes, France

Prof. Stéphane Supiot is a clinician Scientist in the Department of Radiation Oncology at Institut de Cancérologie de l'Ouest, University of Nantes, France.

Prof. Supiot's interests are in developmental therapeutics for pediatric and prostate cancer radiotherapy. His preclinical research interests are hypoxic response modifiers and the vascular response to irradiation.

His clinical areas of research involve biochemically relapsing and oligometastatic prostate cancer. He is principal investigator on several clinical studies in the Groupe d'Etude des Tumeurs Uro Genitales-GETUG group, such as Oligopelvis GETUG P07, Oligopelvis 2 GETUG P12, POSTCARD GETUG P13, CARLHA GEP 12, CARLHA 2 GETUG 33.

INVITED SPEAKERS



Dr Gerry Adams

Dr Gerry Adams is a UK trained clinical oncologist who arrived in Australia in 2010. After completing his Fellowship he has worked as a consultant in regional Queensland for 9 years and was involved in various positions within the Royal Australian and New Zealand College of Radiologists (RANZCR) during that time.

For the last 3 years he has been a member of RANZCR Council and Chair of the Economics and Work Force Committee (EWC). As RANZCR Dean Gerry's position on the Board of Directors of TROG will help maintain the important strategic links and shared values of our two organisations.

Gerry has a particular interest in improving access to quality radiation therapy in regional areas.



TROG 2024 12 - 15 March 2024 Newcastle NSW





A/Prof Haryana Dhillon

Associate Professor Haryana Dhillon (BSc MA PhD) is a Senior Research Fellow, who co-leads the Survivorship Research Group at the University of Sydney. They chair the Scientific Advisory Committee of the Psycho-Oncology Cooperative Research Group.

Haryana has more than 25 years experience in cancer clinical research across a range of investigator-initiated cancer clinical trials. Their research interests are broad encompassing cancer survivorship, health literacy, and interventions for survivorship, symptom management, and psycho-oncology.

Haryana is passionate about rigor in research, practical solutions to tricky problems, and doing what she can to help humans make it to the 22nd century.



Dr Harriet Gee

Dr Harriet Gee is a Staff Specialist in the Department of Radiation Oncology, Westmead Hospital, Sydney. She holds an MBBS/B Med Sci (First Class Honours), from the University of Melbourne, and a DPhil in Molecular Oncology from the University of Oxford, where she studied as a Rhodes Scholar.

As well as clinical practice serving patients with thoracic cancer, she is actively engaged in translational research, co-leading a research program examining cell death after ablative radiotherapy. Dr Gee teaches medical students and advanced trainees and has been involved in curriculum development for the RANZCR.



Dr Fiona Hegi-Johnson

Dr Fiona Hegi-Johnson is a Radiation Oncologist at the Peter MacCallum Cancer Centre in Victoria and Senior Research Fellow at the University of Melbourne.

Clinically, she specialises in the treatment of patients with lung and breast cancer, including a subspecialty interest in stereotactic ablative body radiotherapy (SABR). Fiona is also the Chair of the TROG Lung Subspecialty Group and is the chief investigator on a number of clinical trials in lung cancer.

Fiona's research programme, which is supported by a Victorian Cancer Agency Fellowship, focuses on developing and using novel PET tracers to integrate biological and imaging information into radiotherapy to develop personalized, biologically driven approaches to radiotherapy treatment.



TROG 2024 12 - 15 March 2024 Newcastle NSW





Dr Deme Karikios

Dr Deme Karikios is a medical oncologist at Nepean Hospital in Sydney. He has a clinical and research interest in thoracic and gastrointestinal malignancies.

Deme also has a research interest in costs and value of anticancer drugs, decisions about treatment with expensive unsubsidised anticancer drugs and financial toxicity. He was awarded his PhD in 2019, entitled "The consequences of rising anticancer drug costs in Australia" which he undertook at the NHMRC Clinical Trials Centre, University of Sydney.

Deme is a founding member of the Common Sense Oncology movement and active member of the COSA Financial Toxicity Working Group.

Deme is a co-supervisor of several PhD students and is a senior clinical lecturer at the University of Sydney. Deme has an interest in cancer care policy and is the immediate past chair of the Medical Oncology Group of Australia.



A/Prof Michael Jameson

Assoc. Prof. Michael Jameson FRACP FRCP (Edin.) PhD is Co-director of Cancer Trials New Zealand (CTNZ) based at the University of Auckland, Assistant Dean at the Waikato Clinical Campus, Faculty of Medical and Health Sciences, University of Auckland, and Medical Oncologist at Waikato Hospital, Hamilton. His main research interests gravitate towards collaborative investigator-initiated clinical trials and translational research, including repurposing drugs in oncology. As Co-director of CTNZ since 2022 he works with a team focussed on supporting clinical and scientific researchers to develop investigator-initiated clinical and translational research projects, gain grant funding, and conduct those trials at multiple sites. He is leading a CTNZ project to develop a formal national cancer trials network in New Zealand, aligning with the "Enhancing Aotearoa New Zealand Clinical Trials" project.

This includes a focus on strategies to improve equitable access to clinical trials, which includes developing the clinical research workforce and infrastructure, especially in smaller regional and rural communities. CTNZ collaborated with government agencies, industry bodies and other researchers to successfully develop standard operating procedures for decentralised trials in New Zealand, with such trials now underway.



Dr Susanne Rogers

Susanne Rogers qualified at the University of Cambridge, UK and undertook general medical training and subsequently clinical oncology training in London, UK. She undertook research focusing on targeted EGFR inhibition in head and neck cancer at The Royal Marsden Hospital / Institute of Cancer Research and was awarded a PhD in 2010.

Since then, she lives and works in Switzerland, where she is deputy head of radiotherapy at Kantonsspital Aarau.

Her current clinical and research interests include radiotherapy and radiosurgery for the treatment of primary and secondary brain tumours.

36th TROG Cancer Research Annual Scientific Meeting

Together Towards Tomorrow

R.G.



A/Prof Craig Underhill

Associate Professor Craig Underhill is a medical oncologist at Albury-Wodonga Regional Cancer and Wellness Centre. He is conjoint Associate Professor at the University of NSW Clinical School in Albury, and Adjunct Professor at Charles Sturt University. After training in Melbourne and working as a research fellow at Guys Hospital London and Ludwig Institute Melbourne, he led the development of a medical oncology service in Albury-Wodonga and established an independent not-for-profit Clinical Trials Unit (Border Medical Oncology Research Unit) which has twice been awarded NSW Premier's Award for Innovation in Cancer Clinical Trials.

As the VCCC Regional Oncology Co-Lead he advocates for the increased access to clinical trials for regional Victorians and leads the Victorian Teletrials Collaboration. This program has operationalised teletrial methodology (also known as decentralized clinical trials). He is leading a research program awarded by the Australian Government for AUD\$18.5million over 5 years to implement teletrials and conduct health services research via telehealth across the Regional Trials Network – Victoria.





Hope for everyone dealing with cancer.



Experience the freedom of the most comprehensive radiation therapy ecosystem from Elekta—adaptive, precise and personalized for you, your patients and your practice.

We don't just build technology, we build hope



elekta.com

LADXX221108 © 2023 The Elekta Group. All rights reserved. Elekta Unity, Elekta Studio, Elekta Harmony, Elekta MOSAIQ Plaza and Elekta Esprit are trademarks of Elekta Group and not available in all markets.









PROGRAM

Tuesday 12 March 2024 **Clinical Research Education Workshop (CREW) PROGRAM**

09:00 - 10:30	Joint CREW & TRW Session	Peibri Place
09:00	Susan Goode Sponsored by: Welcome	🕥 Calvary
09:05	Tanya Symons 1. Key changes in the draft of ICH E6 (R3) and the forthcoming Annexe 2 2. Changes in the 2023 National Statement relevant to RCTs	Mater Newcastle
10:30 - 11:00	Morning Tea	
11:00 - 12:30	Welcome Chairs: Bianca Karle & Kelly Skelton	Newcastle Cruising Yacht Club
11:05	Tanya Symons ICH-GCP E6 (R3) Workshop	
12:30 - 13:30	Lunch	
13:30	Sarah Lukeman From Start to Finish: Meaningful Health Consumer Involvement in Clinical R	esearch
14:45	Sarah Lukeman Gillian Mason Murray McLachlan Sue McCullough Panel Discussion	
15:30 - 16:00	Afternoon Tea	
16:00 - 17:00	Terri Davies Empowering Trial Sites: Strategies for ICH-GCP Adherence with optimal Data	a Integrity and Quality
	Sponsored by:	rialDocs







Tuesday 12 March 2024 Technical Research Workshop (TRW) PROGRAM

09:00 - 10:30	Session A: On your marks, get set, go!		Peibri Place
09:00	Susan Goode Welcome	Sponsored by:	🗘 Calvary
09:05	Tanya Symons Good Clinical Practice (GCP) and clinical research essentials.		Mater Newcastle
10:30 - 11:00	Morning Tea		
11:00 - 12:30	Session B: 'Citius, Altius, Fortius' (Faster, higher, stronger) Chairs: Ms. Jenna Dean & Mr. Fahim Siddiqi		
11:00	Jenna Dean & Mr. Fahim Siddiqi Let the games begin. Welcome to the Technical Research Workshop.		
11:05	Sean Watson Sponsor Address: Varian		
11:10	Prof. Stephen Kry It's not whether you win or lose, it's how you play the game. Keynote speaker: The power of data and data sharing.		
11:40	A/Prof. Chris Oldmeadow Gold medals are made in training, but champions are made in I want to do research! Where should I start?	character.	
12:10	Alisha Moore No pain, no gain! Research opportunities - what data does TROG have and how	can I use it?	
12:30 - 13:30	Lunch		







13:30 - 15:00	Session C: Beyond the Podium: Where Dreams Take Flight Chairs: Ms Lucy Sim & A Prof. Nick Hardcastle
13:30	A Prof Nick Hardcastle Every four years, the world stops to watch ordinary people do extraordinary things. The big questions in research and embracing challenges.
	Panel DiscussionProf. Tomas KronA/Prof. Chris OldmeadowDr. Sweet Ping NgProf. Stephen KryDr. Katrina Woodford
14:20	A Prof. Lois Holloway Let's light the Olympic flame.
14:40	Frontiers in automation: overview, application and opportunities in research. Prof. Paul Keall Hypofractionation – a win for patients and the health system. But what are the implications with regard to image guidance and accuracy?
15:00 - 15:30	Afternoon Tea
15:00 - 15:30 15:30 - 16:55	
	Afternoon Tea Session D: Winning is great, but the journey is where the real Olympians are made
15:30 - 16:55	Afternoon Tea Session D: Winning is great, but the journey is where the real Olympians are made Chair: Ms Jenna Dean & Mr. Rob McDowall Hands on session No false starts here – it's time for the final race.
15:30 - 16:55 15:30	Afternoon Tea Session D: Winning is great, but the journey is where the real Olympians are made Chair: Ms Jenna Dean & Mr. Rob McDowall Hands on session No false starts here – it's time for the final race. Hands on Session: How to develop your research idea. Hands on session Go for gold!

TRW Workshops Sponsor



A Siemens Healthineers Company







Tuesday 12 March 2024 Statistical Methods, Evidence Appraisal & Research for Trainees Workshop (SMART) PROGRAM

08:30 - 08:50	Welcome A/Prof Puma Sundaresan – President, TROG Cancer Research	Newcastle Cruising Yacht Club
8:50	Study Design Cohort / case control Aspects of bias Phase 1 and phase 2 designs Randomised controlled trials Randomisation and stratification Non-inferiority / equivalence designs	
09:30	Small Group Session 1	
10:30-10:50	Morning Tea	
10:50	Selecting endpoints Outcome to endpoint Endpoint selection Hazard ratios and Kaplan Meier	
11:10	Small Group Session 2	
12:00	International Guest speaker Professor Stephane Supiot, Institut de Cancérologie de l'Ouest, Universi	ty of Nantes, France.
12:30 - 13:30	Lunch	
13:30	Other issues Sample size considerations Non-compliance Confounders Appropriate follow up time Frequency of data collection Dealing with missing data	
14:25	Small Group Session 3	
15:25-15:45	Afternoon tea	
15:45	National Guest Speaker	
16:15	Critical appraisal wrap-up	
16:35	Closing comments	
17:00 – 18:00	Networking function	





Wednesday 13 March 2024

07:30 - 08:30	Catered Session Clinical Innovation for More Efficient Cancer Care	Banquet Room
	Deepak Khuntia, MD, FASTRO	Sponsored by: A Siemens Healthineers Company
9:00 - 10:30	Welcome & Official Opening Chairs: Joerg Lehmann & Jane Ludbrook	Banquet Room
09:00	Welcome to Country	
09:05	Official Welcome - Councillor Dr Elizabeth Adamczyk, City of N	Newcastle, Lord Mayor's Office
09:10	President's Report - Prof Trevor Leong	
09:20	TROG Scientific Committee Report - A/Prof Sasha Senthi	
09:30	TROG Independent Data and Safety Committee - Prof Bryan B	Burmeister
09:35	International Keynote Address	
	Stéphane Supiot Vascular remodelling during radiotherapy at low and ultra-hig	gh dose rate (Flash) <i>abs#</i> 1
10:30 - 11:00	Morning Tea & Exhibition	Concert Hall







11:00 - 12:30	Plenary Session: Breast Chairs: Farshad Foroudi & Tomas Kron	Banquet Room
	Sponsored by:	
11:00	Farshad Foroudi & Tomas Kron Summary of TROG Breast portfolio abs# 2	ICON
11:10	Emma Connolly Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cance Prospective Multicentre Trial abs# 3	CANCER CENTRE r (AVATAR): A Phase II
11:20	Peter Graham PRELIMINARY RESULTS: TROG 08.06 STARS: A Randomised comparison of before and continuing during adjuvant radiotherapy for breast cancer ve subsequent anti-oestrogen therapy delayed until after radiotherapy. (Ca	ersus anastrozole and
11:30	Verity Ahern RESULTS TROG 12.02 PET LABRADOR: PET scans for locally advanced breast cancer and diagnostic MRI to determine the extent of operation and radiotherapy (Cat A, Open) abs# 5	
11:40	Claire Phillips Local HERO: A Phase II study of local therapy only (stereotactic radiosurgery and/ or surgery) for treatment of up to 5 brain metastases from HER2+ breast cancer. TROG 16.02 abs# 6	
11:50	Nicholas Zdenkowski The intersections between systemic and local therapy for breast cancer: opportunities abs# 7	current status and future
12:15	Peter Griffin Whole breast knowledge-based planning predictions and transferability: consortia experience abs# 8	a transcontinental
12:30 - 13:30	Lunch & Exhibition	Concert Hall
	Catered Session Embracing Innovation and Enhancing Outcomes with Advanced Technology	Banquet Room
	Deepak Khuntia, MD, FASTRO Sponsored	by: A Siemens Healthineers Company







13:30 - 15:00	Plenary Session: Rural & Regional Chair: Patrick Horsley & Michael Penniment	Banquet Room
13:30	Michael Jameson Opportunities for extending cancer clinical trials to NZ rural and regional	locations abs# 9
13:50	Gerry Adams Enablers for the conduct of cancer clinical trials in rural and regional loca	tions abs# 10
14:10	Craig Underhill Learnings from the RTN-Vic and ReViTALISE initiatives: Enabling clinical tr boundaries abs# 11	ial participation across
14:30	Georgia Halkett Investigating Oncologists' attitudes towards the transition of patients to follow-up <i>abs# 12</i>	primary care for treatment
14:40	Panel Discussion: A/Prof Michael Jameson, University of Auckland; Dr Gerry Adams, Royal Australian and New Zealand College of Radiologist Dr Craig Underhill, Albury Wodonga Health/North East Health; A/Prof Georgia Halkett, Curtin University	ts;
15:00 - 15:30	Afternoon Tea, Exhibition & Poster Displays	Concert Hall



TROG 2024 12-15 March 2024 Newcastle NSW



15:30 – 17:00	Plenary Session: Central Nervous System Chairs: Mark Pinkham & Kylie Jung	Banquet Room	
	Sponsored by:	FOUND	
15:30	Mark Pinkham Central Nervous System (CNS) Working Party update <i>abs# 13</i>	THE UNIVERSITY OF NEWCASTLE AUSTRALIA RESEAR	CANCER
15:35	Eng-Siew Koh The prospective, multi-centre trial evaluating FET-PET in Glioblastoma (FIG) study update and current learnings <i>abs#</i> 14) study, TROG 18:06 -	
15:45	Neda Haghighi TD 23.02 Pre-operative radiosurgery for brain metastases (Cat A, In Develo	pment) <i>abs# 15</i>	
15:55	Frank Saran TD 23.02; Discussant <i>abs# 16</i>		
16:10	Susanne Rogers Pre-operative SRS for brain metastases; DEGRO perspective <i>abs# 17</i>		
16:30	Yu Yang Soon What are the next rad onc trials in brain metastases <i>abs# 18</i>		
16:40	Panel Discussion: Prof Frank Saran, Australian Bragg Centre; Dr Yu Yang Soon, National University Cancer Institute, Singapore; Dr Catherine Johnson, John Hunter Hospital; A/Prof Haryana Dhillon, University of Sydney		
	A/Prof James Lynam, Calvary Mater Newcastle		





Thursday 14 March 2024

07:30 - 08:30	Catered Session		Banquet Room
	Unity MR-Linac Global Registry Collaboration and Clinical Update - ONJ Austin Health		
	Sweet Ping Ng, MBBS, PhD, FRANZCR	Sponsored by:	Elekta
09:00 - 10:30	Plenary Session: Genitourinary Chair: Wee Loon Ong & Niluja Thiru		Banquet Room
		Sponsored by:	CElekta
09:00	Stéphane Supiot The GETUG Strategy of clinical trials in oligometas	tatic prostate cancer ab	
9:20	Shankar Siva FASTRACK - Multicentre Phase II Trial of SABR for	Primary Kidney Cancer	abs# 20
9:35	Shankar Siva TROG 19.06 DECREASE: DarolutamidE + Consolida detected by PSMA (Cat A, Open) abs# 21	ition RadiothErapy in Adv	vanced proStatE cancer
9:40	Jarad Martin TROG 18.01 NINJA: Novel Integration of New pros deprivation (Cat A, Open) <i>abs# 22</i>	state radiation schedules	with adJuvant Androgen
9:45 9:53	Wee Loon Ong TD 23.03 2SHOTS; 2-fraction Stereotactic radiothe 23	erapy Of the ProState(C	at A, New Proposal) abs#
5.55	Eric Wegener TD 23.03 2SHOTS: Discussant <i>abs# 24</i>		
10:05	Muhammad Ali TD 23.01 REMASTER; REduced MArgin STEReotact III randomised trial (Cat A, In development) abs# 6		r prostate cancer: A phase
10:15	Niluja Thiru TD 23.04 PEARLS A phase II/III trial of Primary radi patients with Lymph nodeS (Cat B, New Proposal)		sensitive pRostate cancer
10:25	Wee Loon Ong Genitourinary (GU) Working Party update <i>abs# 27</i>	7	
10:30 - 11:00	Morning Tea & Exhibition		Concert Hall





11:00-12:30	Plenary Session: Radiobiology Chair: Eric Hau & Joseph Sia	Banquet Room
11:00	Fiona Hegi-Johnson Seeing Biology: Using novel PET tracers to develop personalised, biologic approaches to radiation therapy treatment <i>abs# 28</i>	ally driven
11:20	Harriet Gee Harnessing cell death mechanisms after ablative radiotherapy to enhanc synergy <i>abs# 29</i>	e immunotherapy
11:40 12:00	Stephen Kry Balancing data collection burden for participating centres and comprehe trial data : An NCI perspective <i>abs# 30</i>	ensive utilization of clinical
12:20	Timothy G Perk Machine learning simulation of targeted ablation for oligoprogressive metastatic prostate cancer <i>abs# 31</i>	
	Panel Session with: Dr Fiona Hegi-Johnson, Peter MacCallum Cancer Centre; Dr Harriet Gee, Westmead Hospital; Prof Stephen Kry, MD Anderson Cancer Centre; Timothy G Perk, AIQ Solutions	
12:30 - 13:30	Lunch, Exhibition & Poster Displays	Concert Hall
13:30 - 15:00	Plenary Session: Lung Chair: Yu Yang Soon & Fiona Hehi-Johnson	Banquet Room Session Sponsored by:
13:30	Jane Ludbrook Moderately hypofractionated chemoradiation followed by immunotherapy for inoperable Stage 3 Non-Small Cell Lung Cancer given with radical intent in older adults (MODERN-LUNG): a randomised trial <i>abs# 32</i>	Varian A Siemens Healthineers Company
13:38	Margot Lehman TD 24.01 MODERN-LUNG: Discussant <i>abs# 33</i>	
13:50	Paul Keall TD 21.08 VITaL; The Ventilation Imaging for Thoracic Lung cancer radiation therapy trial (Cat C, In development) <i>abs# 34</i>	
13:54	Shankar Siva PRIME-LUNG: A randomised phase 3 trial of up-front stereotactic radiotherapy before standard-of- care systemic therapy in advanced lung cancer (Cat C, In development) <i>abs# 35</i>	
13:58	Eric Hau TD 21.09 OCTAVO; A phase II study of consolidation radiation for induced following initial immunotherapy (Cat C, In development) <i>abs# 36</i>	d oligo-persistent disease



36th TROG Cancer Research Annual Scientific Meeting

Together Towards Tomorrow





14:02	Eric Hau TROG 20.01 CHEST RT: A phase II study of carboplatin and etoposide che with or without thoracic radiotherapy in the first line treatment of patie small-cell lung cancer (Cat A, Open) <i>abs# 37</i>	
14:06	Yu Yang Soon TROG 17.02 OUTRUN Randomised phase II trial of Osimertinib with or w radiosurgery for EGFR mutated NSCLC with brain metastases (Cat A, Ope + Cognitive Function analysis <i>abs# 38</i>	
14:10	Nicholas Bucknell Impact of SABR on Pulmonary Function: An Analysis of the TROG13.01 (S	SAFRON II) trial abs# 39
14:18	Lucinda Burke Trial Concept Discussion; Ultracentral <i>abs# 40</i>	
14:25	Jonathan Goodwin 4D MRI for lung tumour motion assessment <i>abs# 41</i>	
14:35	Scott H Twaddell Overview of the National Lung Cancer Screening Program <i>abs# 42</i>	
14:50	Panel Discussion; Opportunities for TROG research with the implement Cancer Screening Program: Dr Scott Twaddell, John Hunter Hospital; Sue McCullough AM, TOGA & TROG; A/Prof Harriet Gee, Westmead Hospital; Dr Peng Seah, John Hunter Hospital	tation of National Lung
14:55	Yu Yang Soon Lung Working Party Update <i>abs#43</i>	
15:00-15:30	Afternoon tea	Concert Hall





15:30 - 1700	Plenary Session: Health Economics & Quality of LifeBanquet RoomChairs: Paul Keall & Shalini VinodEndersity of Life		
15:30	Deme Karikios Tackling financial toxicity: Isn't it just common sense? <i>abs# 44</i>		
15:50	Puma Sundaresan A new Patient Reported Measure for use in clinical trials comparing shorter fractionation with conventional schedules: measuring RT related "inconvenience" <i>abs# 45</i>		
16:00	Haryana Dhillon Symptoms in Cancer Survivorship: How patient-reported outcomes can guide intervention research <i>abs# 48</i>		
16:20	Puma Sundaresan Multidisciplinary, patient informed and patient centred research:The "problem" that informed the "Remove the mask" program of research <i>abs# 47</i>		
16:30	Youssef Y Ben Bouchta Multidisciplinary, patient informed and patient centred research: Using technology to "Remove the mask" <i>abs# 46</i>		
16:40	Panel Discussion with: Dr Deme Karikios, Nepean Cancer Car Centre A/Prof Puma Sundersan, NSW Health A/Prof Haryana Dhillion, University of Sydney Dr Youssef Ben Bouchta, University of Sydney		

15 March 2024

Newcastle NSW





TROG 2024 12 - 15 March 2024 Newcastle NSW



Friday 15 March 2024

09:00 - 10:30	Plenary Session: Head, Neck and Skin Chairs: Charles Lin & Sweet Ping Ng	Banquet Room
09:00	Session Sponsor: Danny Rischin NRG-HN014 / TD 24.02: Randomized Phase III Trial of Peri-opera Response-adjusted Surgery versus Standard-of-Care (SOC) Surge Cutaneous Squamous Cell Carcinoma (CSCC) (Cat B, NewProposa	ry for Resectable Stage III/IV
09:15	Wen Xu MASC 03.18 / TROG 21.01 IMAT: Immunotherapy Merkel Adjuva	nt Trial (Cat C, Open) abs# 50
09:20	Sweet Ping Ng Stereotactic radiotherapy for head and neck cancer <i>abs# 51</i>	
09:40	Stephen Kry Best way for dose accumulation assessments and/or HN SBRT QA	A what to watch out for <i>abs# 52</i>
10:00	Joe Chang Radiobiological modelling of the effectiveness of stereotactic rad cancer <i>abs# 53</i>	liotherapy for head and neck
10:20	Charles Lin Head, Neck and Skin (HNS) Working Party update abs# 54	
10:30 - 11:00	Morning Tea & Exhibition	Concert Hall







11:00 - 12:30	Plenary Session: Research Highlights & InsightsBanquet RoomChairs: Jenna Dean & Vanessa PanettieriEndersi		
11:00	Chandrima Sengupta TROG 17.03 LARK: Liver Ablative Radiotherapy utilising Kilovoltage Intrafraction Monitoring (KIM) <i>abs# 55</i>		
11:10	David Pryor TROG 21.07 SOCRATES HCC: A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma <i>abs# 56</i>		
11:20	Hien Le TROG 21.12 ASPIRE: Australian Proton Therapy Clinical Quality Registry (APTCQR) <i>abs# 57</i>		
11:29	Kelly Skelton Preliminary Insights and Development of the Australian Particle Therapy Clinical Quality Registry - ASPIRE TROG 21.12 <i>abs# 58</i>		
11:35	Wee Loon Ong Androgen deprivation therapy and radiation therapy for prostate cancer – where are we two decades post TROG9601/TROG0304? <i>abs# 59</i>		
11:41	Aleksandra Kazi Radiomics to predict survival in people with glioma using pre-operative imaging only: impact of volume selection for feature extraction <i>abs# 60</i>		
11:47	Chandrima Sengupta An open-source project for managing clinical trial data: Making data accessible, usable, interoperable, and secure <i>abs# 61</i>		
11:53	Rhonda Brown Participation in high quality audits is necessary for better cancer outcomes <i>abs# 62</i>		
11:59	Su Chen Fong Histopathological correlation with Magnetic Resonance (MR) Imaging from MR-simulator and MR- Linac in Oesophageal and Gastric Cancers <i>abs# 63</i>		
12:05	Joerg Lehmann Improving Patient Specific Quality Assurance – The SEAFARER Australia project abs# 64		
12:30 - 12:45	Meeting Close & Introduction to ASM 2025Banquet RoomJoerg Lehmann & Jane Ludbrook		
12:45 - 13:30	Lunch & ExhibitionConcert HallGrab and go lunch boxes		

36th TROG Cancer Research Annual Scientific Meeting

Together Towards Tomorrow

TROG 2024 12 - 15 March 2024 Newcastle NSW





PUSH THE BOUNDS OF SCIENCE MAKE LIFE-CHANGING MEDICINES

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development.

Learn more at www.regeneron.com/global

REGENERON®



POSTER LISTING

Nathaniel Barry

Computational analysis and artificial intelligence approaches for the FET PET in Glioblastoma (FIG) Trial - TROG 18.06 abs# 101

Neil D Wallace

The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small cell lung cancer abs# 102

Carrie-Anne Ng

Using conceptual frameworks to guide the selection of Patient Reported Outcome Measures in cancer clinical trials: A CQUEST Resource abs# 103

Neil D Wallace

The impact of age on survival after chemoradiotherapy for stage III NSCLC abs# 104

Ryan Motley

Deep learning-based automated assessment of prostate motion during radiotherapy treatment abs# 105

Jose A Baeza-Ortega

Clinical evaluation of a real-time treatment verification system for stereotactic body radiotherapy abs# 106

Alisha Moore

Treatment plan quality review with knowledge-based planning in the TROG 18.01 NINJA trial abs# 107

36th TROG Cancer Research Annual Scientific Meeting Together Towards Tomorrow

SPONSOR & EXHIBITOR PROFILES

EVENT PARTNER Varian www.varian.com

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy, to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com.

PLATINUM SPONSORS Elektra www.elektra.com

As a leader in precision radiation therapy for more than 50 years and beyond, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven, and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Contact us at ANZ-Sales@elekta.com.


Icon Cancer Centre www.iconcancercentre.com

Icon Cancer Centre is part of Icon Group - Australia's largest dedicated cancer care provider. The Group has expanded globally into Singapore, Mainland China, Hong Kong and New Zealand and has a strong history of cancer research, now operating the largest private cancer clinical trials program in Australia. Icon Group has 39 cancer centres in Australia with several centres in development, including day oncology hospitals, radiation oncology facilities and comprehensive centres that bring both oncology disciplines together.

The Group also encompasses Slade Health: one of Australia's largest chemotherapy compounders with three TGAapproved manufacturing sites across the eastern seaboard; and supports Epic and Slade Pharmacy: providers of medication management and pharmacy services to the hospital and oncology sectors. For more information visit www.icongroup.global and follow us on social media @IconGroup



29



Elekta

/arian







GOLD SPONSOR Regeneron www.regeneron.com

REGENERON

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for over 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite[®] technologies, such as VelocImmune[®], which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For more information, please visit https://www.regeneron.com/global or follow Regeneron on LinkedIn

BRONZE & WELCOME RECEPTION SPONSOR Brainlab www.brainlab.com

www.brainab.com

Brainlab is a digital medical technology pioneer founded in 1989 and headquartered in Munich. The company employs 2200 people in 25 locations around the globe. Brainlab serves physicians, medical professionals and their patients in over 6300+ hospitals in 122 countries. Brainlab creates software-driven medical solutions that digitize, automate and optimize clinical workflows for neurosurgery, spine, trauma, craniomaxillofacial (CMF), general and vascular surgery as well as radiotherapy and radiosurgery. Core products center around surgical navigation, radiotherapy, digital operating room integration, and information and knowledge exchange. Brainlab is dedicated to creating an impact in healthcare.

BRONZE SPONSORS

Australian Clinical Dosimetry Service (ACDS) www.arpansa.gov.au

The Australian Clinical Dosimetry Service (ACDS) is a world class independent dosimetry auditing program that aims to provide a high standard of quality assurance and patient safety in radiation therapy across Australia and New Zealand. Operating since February 2011, it offers a multi-level dosimetry audit service on a four-year subscription basis to radiotherapy providers. Our comprehensive radiotherapy audit services allow benchmarking of audit results to the Australian and New Zealand dataset. The ACDS offers dosimetry audits to meet Radiation Oncology Practice Standards (ROPS), Radiation Oncology Health Program Grants (ROHPG) funding, TROG clinical trial credentialling and jurisdictional radiation licensing requirements.

AIQ Solutions www.aig-solutions.com

AIQ Solutions is empowering a new era of clinical decision support for Oncology.

AIQ's TRAQinform IQ is a cloud-based, machine learning-powered, software medical device that provides clinical decision support for physicians treating patients with late-stage metastatic cancer.


AIQ offers the only technology that can quantify and classify the change for each region of interest identified on PET/CT images, providing essential information helping Oncologists, Nuclear Medicine Physicians and Radiation Oncologists to make more confident treatment decisions, personalise care, and improve patient outcomes. (ARTG Code: 402321)











36th TROG Cancer Research Annual Scientific Meeting

Together Towards Tomorrow

alpha XRT www.alphaxrt.com

alphaXRT is Australasia's leading independent supplier of radiotherapy equipment. Our real-world experience and industry expertise help customers throughout the region in providing unparalleled patient care.

We seek the very best, bringing cutting-edge equipment and specialist staff together. Our customers and their patients are our number one priority: we are deeply committed to providing all patients a future with options.

AstraZeneca

www.astrazeneca.com.au

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

Cipla

https://www.cipla.com/

Cipla is a global healthcare company that strives to make a difference in the lives of patients around the world. With our focus on oncology and urology, we provide quality care for those who need it most. Our guiding principle of "Caring for Life" drives us to make a difference in every aspect of our work. With over 100 years of experience, Cipla is committed to making quality healthcare accessible to everyone.

Mundipharma Pty Limited

www.mundipharma.com

Mundipharma is committed to providing products which give people the best possible quality of life and make a difference where it matters most. Our collaborative relationships with our stakeholders are at the centre of how we operate and we take great pride in knowing that the work we do benefits healthcare professionals and their patients. With our product portfolio including Androgen Deprivation Therapy (ADT) for advanced prostate cancer, we encourage you to visit our website for healthcare professionals, https://www.mundipharmapro.com/en-au/ where you will have access on demand to medicine information and resources for both healthcare professionals and patients.

Oxford Scientific


https://www.oxfordscientific.com.au/

Oxford Scientific Australia is a trusted distributor of high-value medical and scientific equipment from leading global radiotherapy manufacturers including Limbus, Standard Imaging, Xstrahl, ScandiDos, RSD and Ross Engineering.



pharma





AstraZene







INTRODUCING HYPERSIGHT" AREVOLUTION INRESOLUTION

An epic advancement in **image quality, precision, and speed.**

The next generation of in-treatment-room imaging: now available for Halcyon[®] radiotherapy system and Ethos[™] therapy.

Experience HyperSight at varian.com/hypersight

© 2023 Varian Medical Systems, Inc. All rights reserved. Varian, Varian Medical Systems, and Halcyon are registered trademarks and Ethos and HyperSight are trademarks of Varian Medical Systems, Inc. Not available for sale in all markets. Refer enquiries to Varian Medical Systems Australasia on 1800 457.036 or custamerservice-anz@varian.com

